A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PARTICIPANTS WITH ENDOMETRIAL CANCER WHO HAVE RECEIVED PRIOR PLATINUM-BASED CHEMOTHERAPY AND ANTI-PD-1/PD-L1 IMMUNOTHERAPY
- Registry ID
- GS-US-682-6769
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- GILEAD SCIENCES CANADA INC
- Start date
- 2025-03-31
- Last update
- 2024-08-07
Conditions
Related clinical trials
- A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH RECURRENT ENDOMETRIAL CANCER
- A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF RINATABART SESUTECAN (RINA-S) VERSUS TREATMENT OF INVESTIGATOR’S CHOICE (IC) IN PATIENTS WITH ENDOMETRIAL CANCER AFTER PLATINUM-BASED CHEMOTHERAPY AND PD(L)-1 THERAPY
- Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL TRIAL OF TRASTUZUMAB
DERUXTECAN VERSUS STANDARD OF CARE CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY
AS ADJUVANT TREATMENT FOR HER2-EXPRESSING (IHC 3+/2+) ENDOMETRIAL CANCER
(DESTINY-ENDOMETRIAL02/ GOG-3122/ENGOT-EN30/GINECO)
- A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE
EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN IN COMBINATION WITH
PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE
TREATMENT IN PARTICIPANTS WITH MISMATCH REPAIR PROFICIENT ENDOMETRIAL
CANCER (TROFUSE-033/GOG-3119/ENGOT-EN29)
- A PHASE III, RANDOMIZED, MULTI-SITE, OPEN-LABEL TRIAL OF BNT323/DB-1303 VERSUS
INVESTIGATOR¿S CHOICE OF CHEMOTHERAPY IN PREVIOUSLY TREATED PATIENTS WITH HER2-
EXPRESSING RECURRENT ENDOMETRIAL CANCER
View on source registry